e-NIOS Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $25.5K

  • Investors
  • 3

e-NIOS General Information

Description

Operator of genomic data analysis and interpretation platform designed to automate biomarker discovery for precision medicine. The company's platform offers an unsupervised analysis of complex genomic, and multi-omic data, and accelerates the discovery of critical biomarkers, and the technology incorporates biological knowledge into data mining, enabling researchers to deliver novel molecular markers or targets for diagnostics and therapeutics.

Contact Information

Website
www.e-nios.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Corporate Office
  • L. Syggrou 196
  • Kallithea
  • Athens, Attiki 176 71
  • Greece
+30 21 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

e-NIOS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 28-Jul-2022 $25.5K 00000 Completed Generating Revenue
2. Seed Round 01-Jan-2017 00000 00000 Completed Generating Revenue
1. Seed Round 14-Dec-2015 $215K $215K Completed Generating Revenue
To view e-NIOS’s complete valuation and funding history, request access »

e-NIOS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of genomic data analysis and interpretation platform designed to automate biomarker discovery for precision med
Drug Discovery
Athens, Greece
10 As of 2023
00000
000000000000 00000

000000

elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
00000 0000000000 000
Rolle, Switzerland
000 As of 0000
00000
000000000 00000

000000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000000000000
Hilden, Germany
0000 As of 0000
00000
000.00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

e-NIOS Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
SOPHiA GENETICS Formerly VC-backed Rolle, Switzerland 000 00000 000000000 00000
Qiagen Formerly VC-backed Hilden, Germany 0000 00000 000000&0
Roche Diagnostics Corporation Rotkreuz, Switzerland 000000
You’re viewing 3 of 3 competitors. Get the full list »

e-NIOS Patents

e-NIOS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022512626-A Methods and pharmaceutical compositions for the treatment of mucosal inflammatory diseases Pending 04-Oct-2018 00000000000 0
EP-3861022-A1 Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases Pending 04-Oct-2018 000000000
US-20210340278-A1 Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases Pending 04-Oct-2018 000000000
US-20200318203-A1 Method of selection of an ire1-inhibitor therapy for patient suffering from cancer Active 20-Dec-2017 0000000000
US-11525165-B2 Method of selection of an ire1-inhibitor therapy for patient suffering from cancer Active 20-Dec-2017 C12Q1/6886 0
To view e-NIOS’s complete patent history, request access »

e-NIOS Executive Team (3)

Name Title Board Seat Contact Info
Aristotelis Chatziioannou Ph.D Co-Founder, Chief Scientific Officer & Chief Executive Officer
Eleftherios Pilalis Ph.D Co-Founder & Chief Technology Officer
You’re viewing 2 of 3 executive team members. Get the full list »

e-NIOS Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

e-NIOS Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer (Pharmaceuticals) Corporation 000 0000 000000 0
IQbility Accelerator/Incubator Minority 000 0000 000000 0
PJ Tech Catalyst Venture Capital Minority 000 0000 000000 0
To view e-NIOS’s complete investors history, request access »

e-NIOS FAQs

  • When was e-NIOS founded?

    e-NIOS was founded in 2013.

  • Who is the founder of e-NIOS?

    Aristotelis Chatziioannou Ph.D, Eleftherios Pilalis Ph.D, and Ioannis Valavanis Ph.D are the founders of e-NIOS.

  • Who is the CEO of e-NIOS?

    Aristotelis Chatziioannou Ph.D is the CEO of e-NIOS.

  • Where is e-NIOS headquartered?

    e-NIOS is headquartered in Athens, Greece.

  • What is the size of e-NIOS?

    e-NIOS has 10 total employees.

  • What industry is e-NIOS in?

    e-NIOS’s primary industry is Drug Discovery.

  • Is e-NIOS a private or public company?

    e-NIOS is a Private company.

  • What is e-NIOS’s current revenue?

    The current revenue for e-NIOS is 00000.

  • How much funding has e-NIOS raised over time?

    e-NIOS has raised $341K.

  • Who are e-NIOS’s investors?

    Pfizer (Pharmaceuticals), IQbility, and PJ Tech Catalyst have invested in e-NIOS.

  • Who are e-NIOS’s competitors?

    SOPHiA GENETICS, Qiagen, and Roche Diagnostics are competitors of e-NIOS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »